Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 410
Gene Symbol: ARSA
ARSA
0.070 AlteredExpression group BEFREE Bone marrow stem cell gene therapy in mice, using a retroviral vector mediating expression of wild-type human ASA, has the potential to ameliorate the visceral pathology, but improves the prevailing brain disease and neurologic symptoms only marginally. 11399225 2001
Entrez Id: 410
Gene Symbol: ARSA
ARSA
0.070 GeneticVariation group BEFREE A 9-bp deletion (2320del9) on the background of the arylsulfatase A pseudodeficiency allele in a metachromatic leukodystrophy patient and in a patient with nonprogressive neurological symptoms. 9490297 1998
Entrez Id: 410
Gene Symbol: ARSA
ARSA
0.070 AlteredExpression group BEFREE Out of 8 cases with neurological symptoms and low ASA activity, 2 were found to be homozygous for the Pd allele; 2 MLD patients had healthy siblings homozygous for the Pd allele and another patient's allele bore two mutations, Pd and that causing MLD. 8946177 1996
Entrez Id: 410
Gene Symbol: ARSA
ARSA
0.070 GeneticVariation group BEFREE Analysis of the two PD mutations in the ASA gene separately was carried out in a large group of subjects with neurological symptoms and low ASA activity, including close relatives and MLD patients. 8750609 1995
Entrez Id: 410
Gene Symbol: ARSA
ARSA
0.070 GeneticVariation group BEFREE Thus, increasing sulfatide storage in ASA(-/-) mice leads to neurological symptoms and morphological alterations that are reminiscent of human MLD. 17728461 2007
Entrez Id: 410
Gene Symbol: ARSA
ARSA
0.070 GeneticVariation group BEFREE We conclude that the observed neurological symptoms are unrelated to the ASA genotype and that PD/MLD compound heterozygotes are not at an increased risk for developing progressive nervous system diseases. 8095368 1993
Entrez Id: 411
Gene Symbol: ARSB
ARSB
0.010 Biomarker group BEFREE Although enzyme replacement therapy has become available for some MPS types (MPS I, MPS II and MPS VI), this treatment is not efficient when neurological symptoms occur, especially in MPS III (Sanfilippo disease). 19690584 2010
Entrez Id: 414
Gene Symbol: ARSD
ARSD
0.010 Biomarker group BEFREE Compensatory changes that reset the rate of proteostasis may contribute to the neurological symptoms of ASD/ID. 27365114 2016
Entrez Id: 170302
Gene Symbol: ARX
ARX
0.010 Biomarker group BEFREE We present a detailed description of the neurological symptoms and the disease history of two brothers with the clinical features of PRTS. 12376938 2002
Entrez Id: 472
Gene Symbol: ATM
ATM
0.030 AlteredExpression group BEFREE These findings offer important new insights into the human disease and the role of brain ATM activity in the severity of the neurological symptoms of A-T. 21593342 2011
Entrez Id: 472
Gene Symbol: ATM
ATM
0.030 GeneticVariation group BEFREE Even before the identification of ATM mutations, it was clear that other diseases with different genomic loci had very similar neurological symptoms. 25038946 2014
Entrez Id: 472
Gene Symbol: ATM
ATM
0.030 Biomarker group BEFREE The growing list of ATM functions that go beyond its role in the DNA damage response offers a new perspective on why individuals with A-T express such a wide range of neurological symptoms, and suggests that not all A-T symptoms need to be understood in the context of the DNA repair process. 23707635 2013
Entrez Id: 478
Gene Symbol: ATP1A3
ATP1A3
0.010 GeneticVariation group BEFREE ATP1A3 mutation analysis is appropriate to consider in the diagnostic algorithm for any child presenting with episodic or fluctuating ataxia, weakness or dystonia whether they manifest persistence of neurological symptoms between episodes. 25447930 2015
Entrez Id: 538
Gene Symbol: ATP7A
ATP7A
0.320 Biomarker group CTD_human Maternofetal and neonatal copper requirements revealed by enterocyte-specific deletion of the Menkes disease protein. 23064757 2012
Entrez Id: 538
Gene Symbol: ATP7A
ATP7A
0.320 Biomarker group CTD_human Prenatal treatment of mosaic mice (Atp7a mo-ms) mouse model for Menkes disease, with copper combined by dimethyldithiocarbamate (DMDTC). 22815746 2012
Entrez Id: 538
Gene Symbol: ATP7A
ATP7A
0.320 GeneticVariation group BEFREE Based on review of X-inactivation patterns in female carriers of other X-linked recessive diseases, our findings imply that substantial expression of a mutant ATP7A at the expense of the normal allele could be associated with neurologic symptoms in female carriers of Menkes disease and its allelic variants, occipital horn syndrome, and ATP7A-related distal motor neuropathy. 20497190 2011
Entrez Id: 538
Gene Symbol: ATP7A
ATP7A
0.320 GeneticVariation group BEFREE He has few neurological symptoms without connective tissue disturbances; and a missense ATP7A variant, p.(Pro852Leu), which results in impaired protein trafficking while the copper transport function is spared. 28657131 2017
Entrez Id: 540
Gene Symbol: ATP7B
ATP7B
0.010 GeneticVariation group BEFREE Wilson's disease (WD) is an autosomal recessively inherited copper storage disorder due to mutations in the ATP7B gene that causes hepatic and neurologic symptoms. 26409215 2016
Entrez Id: 6310
Gene Symbol: ATXN1
ATXN1
0.010 Biomarker group BEFREE Spinocerebellar ataxia (SCA) type 1 (SCA1) is a rare autosomal dominant disorder that is characterized by worsening of disordered coordination, ataxia of the trunk, and other neurological symptoms. 31271500 2019
Entrez Id: 4287
Gene Symbol: ATXN3
ATXN3
0.020 Biomarker group BEFREE We describe three patients with the Machado-Joseph disease (MJD) genetic abnormality who had non-movement disorder neurological symptoms or signs that preceded the gait ataxia by several years. 15747372 2005
Entrez Id: 4287
Gene Symbol: ATXN3
ATXN3
0.020 Biomarker group BEFREE Ataxin-3-Q79 transgenic mice displayed motor dysfunction with an onset age of 5-6 months, and neurological symptoms deteriorated in the following months. 18502140 2008
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.010 GeneticVariation group BEFREE We collected CSF from patients with BRAF V600E or K-mutated melanoma (N=8) or BRAF V600E mutated Erdheim-Chester Disease (ECD) (N=3) with suspected central nervous system (CNS) involvement on the basis of neurological symptoms (10/11), MRI imaging (8/11), or both. 27863426 2016
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.010 Biomarker group BEFREE Diagnosis of PML-IRIS should be considered in HIV-infected patients with worsening neurological symptoms after initiation or resumption of effective cART, independently of CD4 cell count prior to cART. 28588577 2017
Entrez Id: 773
Gene Symbol: CACNA1A
CACNA1A
0.010 Biomarker group BEFREE We show that FHM genes are involved in at least a proportion of SHM patients without associated neurologic symptoms. 18056581 2007
Entrez Id: 846
Gene Symbol: CASR
CASR
0.010 Biomarker group BEFREE A newly developed CAR-T-specific neurological symptom checklist (NSC) was completed by caregivers at 3 designated time-points. 30048343 2018